van de Donk NWCJ, Moreau P, San-Miguel JF, Mateos MV, Dimopoulos MA, Zweegman S, Gay F, Engelhardt M, Mina R, Zamagni E, Delforge M, Beksac M, Spencer A, Schjesvold F, Driessen C, Kaiser M, Perrot A, Wäsch R, Korst CL, Broijl A, Touzeau C, Manier S, Hajek R, Ludwig H, Fernandez de Larrea C et al. (2025)
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network
Lancet Haematol (in press)
DOI 10.1016/S2352-3026(25)00117-6, PubMed 40580975

Ailawadhi S, Špička I, Spencer A, Lu J, Oriol A, Ling S, Schjesvold F, Berkovits A, Hus M, Li C, Dimopoulos MA, Rajnics P, Beşışık SK, Hungria V, Custidiano MDR, Parmar G, Leleu X, Li F, Cerchione C, Gomez C, Ishida T, Mateos MV, Buck TT, LeBlanc R, Minařík J et al. (2025)
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
J Clin Oncol, JCO2500744 (in press)
DOI 10.1200/JCO-25-00744, PubMed 40459178

Raab MS, Cohen YC, Schjesvold F, Aardalen K, Oka A, Spencer A, Wermke M, Souza AD, Kaufman JL, Cafro AM, Ocio EM, Doki N, Henson K, Trabucco G, Carrion A, Bender FC, Juif PE, Fessehatsion A, Fan L, Stonehouse JP, Blankenship JW, Granda B, De Vita S, Lu H (2025)
Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody
Leukemia, 39 (6), 1545
DOI 10.1038/s41375-025-02516-7, PubMed 40374810